CoChat

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Open access

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective: To study immune responses in HCC patients treated with tremelimumab and durvalumab. Design: We treated 28 HCC patients with durvalumab, tremelimumab and locoregional therapies. We performed a high-dimensional multiomics analysis including whole exome sequencing, single-cell RNA seq, CO-Detection by indEXing, flow cytometry and multiplex cytokine/chemokine analysis of patients’ blood and tumour samples and integrated this data to elucidate immune correlatives and response mechanisms. Mice with syngeneic HCC were treated with anti-PD-L1 plus anti-CTLA4 for hepatic lymphocytes, tumour-infiltrating lymphocytes and peripheral blood mononuclear cell analysis. Results: The median overall survival was 19.2 months. Tumour tissue analysis revealed enhanced interferon responses, with stronger effects in responders. Gene set variation analysis indicated enhanced antigen presentation in responders. Spatial analysis revealed that non-responder tumours had higher numbers of Tregs located in neighbourhoods enriched with immune cells and expressed higher levels of ICOS and PD-1. Conversely, non-responder PD1+CD8+T in these Treg-enriched neighbourhoods expressed lower ICOS. Cell-communication analysis demonstrated that Treg-CD8+T interaction was enhanced in non-responder tissue. Peripheral blood analysis showed increased classical monocytes in responders and Tregs in non-responders. Treg-CD8+T interaction was confirmed in preclinical models. Finally, single-patient computational analysis from the all-across analysis was performed on 860 features, which led to the identification of multiomics feature sets including Treg features. Conclusion: Our study provides a blueprint for in-depth analysis of immune correlates in immunotherapy studies and demonstrates the importance of Treg distribution in HCC. Trial registration numbers: NCT02821754 and the EudraCT identifier: 2019-002767-98.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2024-334026

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 28

Metadata

Authors
Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., Cantwell, C., Ryan, R., McCann, J., Bourke, M., Mac Nicholas, R., McDermott, R., Awosika, J., Cam, M., Krebs, R., Budhu, A., Revsine, M., Figg, W. D., Kleiner, D. E., Redd, B., Wood, B. J., Wang, X. W., Korangy, F., Claassen, M., & Greten, T. F.
Affiliations
  • National Institutes of Health (US)
  • Universitätsklinikum Tübingen (DE)
  • Collaborative Protein Technology Resources, Office of Science and Technology Resources, National Institutes of Health, Bethesda, Maryland, USA
  • Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
  • Mater Misericordiae University Hospital (IE)
  • University College Dublin (IE)
  • St Vincent’s University Hospital, University College Dublin, Dublin, Ireland
Corresponding author
Greten, Tim F
Venue
Gut
Publisher
BMJ
Published
2025-02-18
Volume
74
Issue
6
Pages
983-995
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4407690978
Cited by
24
References
38
Citations by year
2026: 9 · 2025: 15
FWCI
9.94
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Japan Society for the Promotion of Science (NIH-KAITOKU #060042)
  • Germany’s Excellence Strategy (EXC 2180 – 390900677)
  • the Intramural Research Program of the NIH, NCI (BC 011343, BC 011870)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
hepatocellular carcinoma, tremelimumab, durvalumab, immune checkpoint inhibitors, tumor-infiltrating lymphocytes, regulatory T cells, CD8+ T cells, ICOS, PD-1, interferon response, antigen presentation, classical monocytes, tumor microenvironment, immunotherapy response, multi-omics, intercellular communication, syngeneic mouse model
MeSH terms
Multiomics, Aged, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. https://app.cochat.ai/papers/10.1136/gutjnl-2024-334026
The paper
Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., . . . Greten, T. F. (2025). Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut. https://doi.org/10.1136/gutjnl-2024-334026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.